Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas
Status:
Completed
Trial end date:
2019-12-16
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of Temozolomide for second-line treatment of Neuroendocrine
Carcinomas progressing after first-line Platinum-based therapy.